Leukemias

Leukemia is cancer of the blood-forming cells — a malignant clone that starts in the bone marrow and spills into the bloodstream. Instead of maturing into functional white cells, red cells, and platelets, the marrow fills with abnormal cells that crowd out normal production. The result is a paradox that trips up many students: a patient may have a very high white-cell count on paper yet be profoundly immunodeficient, because those cells are useless. Understanding leukemia means understanding two independent questions — how fast is it growing, and which cell line is it from — and that two-by-two framework unlocks almost everything about diagnosis, prognosis, and treatment.

Leukemia is also one of oncology's great success stories. Childhood acute lymphoblastic leukemia went from near-uniformly fatal in the 1950s to roughly 90% cured today, and chronic myeloid leukemia was transformed from a death sentence into a chronic, pill-managed condition within a single decade. Few areas of medicine reward understanding the underlying biology as directly.

Learning Objectives

• Classify leukemias along two axes: acute versus chronic, and myeloid versus lymphoid.
• Explain the pathophysiology of marrow failure and the clinical triad it produces.
• Describe the diagnostic workup: blood film, bone marrow, flow cytometry, cytogenetics, and molecular testing.
• Understand the Philadelphia chromosome and why it revolutionized cancer therapy.
• Outline modern treatment principles for AML, ALL, CML, and CLL.
• Recognize oncologic emergencies associated with leukemia.

Quick Answer

Leukemias are malignancies of hematopoietic cells classified by speed (acute = immature blasts, rapid, weeks; chronic = more mature cells, indolent, months to years) and lineage (myeloid or lymphoid). This gives four major types: AML (acute myeloid), ALL (acute lymphoblastic), CML (chronic myeloid), and CLL (chronic lymphocytic). Acute leukemias present with marrow failure — anemia, infection, and bleeding — plus circulating blasts. Diagnosis rests on the blood film, bone marrow biopsy, flow cytometry (immunophenotyping), and cytogenetic/molecular studies. CML is defined by the Philadelphia chromosome (BCR-ABL1 fusion), now treated with tyrosine kinase inhibitors such as imatinib. Therapy ranges from intensive chemotherapy and stem-cell transplant to targeted agents and immunotherapy.

Where It Came From

Before the 19th century, blood was understood only in the crudest terms. In 1845, working independently, the Scottish physician John Hughes Bennett and the German pathologist Rudolf Virchow described patients whose blood, on standing or at autopsy, appeared to contain a thick layer of whitish material. Virchow, examining it under the microscope, recognized a genuine excess of colorless (white) cells rather than pus. In 1847 he coined the term "leukämie" — from the Greek leukos (white) and haima (blood), literally "white blood." The naming mattered: it framed the condition as a disorder of the blood cells themselves, seeding the entire discipline of hematology. Virchow's broader dictum, omnis cellula e cellula ("every cell from a cell"), also foreshadowed the idea that cancer arises from the uncontrolled division of existing cells.

For a century, leukemia was described but untreatable. The real motivation for modern therapy came from two directions. First, in the 1940s Sidney Farber, observing that folic acid accelerated childhood leukemia, reasoned that a folate antagonist might slow it — aminopterin produced the first temporary remissions in ALL in 1948, birthing chemotherapy. Second, and more revolutionary, came 1960 in Philadelphia. Peter Nowell and David Hungerford noticed that patients with CML consistently carried an abnormally small chromosome 22, which they named the Philadelphia chromosome. In 1973 Janet Rowley showed it was not a deletion but a translocation — a swap of material between chromosomes 9 and 22. This was the first consistent chromosomal abnormality ever tied to a specific cancer, and it proved that cancer could be a genetic disease with a discrete, definable cause. Decades later that insight was cashed in: the fusion gene BCR-ABL1 encodes an always-on tyrosine kinase, and in 2001 imatinib (Gleevec) was designed to block it precisely — the poster child of targeted cancer therapy.

The Two-Axis Classification

Everything begins with a single stem cell that has gone wrong. The two axes tell you which one and when.

Acute versus chronic is about maturation, not merely tempo. In acute leukemia the malignant clone is stuck at an immature stage — it produces blasts, primitive cells that cannot function and cannot mature. Blasts pile up rapidly, so acute leukemia presents over days to weeks and is fatal within weeks to months if untreated. In chronic leukemia the clone retains the ability to differentiate, so the blood fills with more mature-looking (if abnormal) cells. It is indolent, often found incidentally on a routine blood count, and can smolder for years.

Myeloid versus lymphoid is about the cell of origin. The myeloid line gives rise to granulocytes, monocytes, red cells, and platelets. The lymphoid line gives rise to B and T lymphocytes. A leukemia is named for its lineage.

Combining the axes gives the four classic types:

Type	Speed	Lineage	Typical patient	Hallmark
AML	Acute	Myeloid	Adults, median ~68 yr	Myeloblasts, Auer rods
ALL	Acute	Lymphoid	Children (peak 2–5 yr)	Lymphoblasts; commonest childhood cancer
CML	Chronic	Myeloid	Middle-aged adults	Philadelphia chromosome (BCR-ABL1)
CLL	Chronic	Lymphoid	Older adults	Smudge cells, mature B lymphocytes

Pathophysiology: Why Patients Get Sick

The clinical picture of acute leukemia flows directly from one idea: the marrow is a fixed-volume factory, and the leukemic clone evicts the normal tenants. As blasts fill the marrow, normal hematopoiesis collapses, producing a triad:

• Anemia (low red cells): fatigue, pallor, breathlessness.
• Neutropenia (low functional neutrophils): fever and infections, often the presenting event.
• Thrombocytopenia (low platelets): bruising, petechiae, gum bleeding, nosebleeds.

Note the trap: the total white count may be high, normal, or low, but the functional count is what matters. A patient with a white count of 80,000 made entirely of blasts is dangerously immunosuppressed.

Additional features depend on type. Leukemic cells can infiltrate organs — gum hypertrophy and skin deposits in monocytic AML, lymphadenopathy and hepatosplenomegaly in lymphoid disease, testicular or CNS involvement in ALL. Very high blast counts cause leukostasis (sludging in small vessels, causing hypoxia and stroke-like symptoms) and set the stage for tumor lysis syndrome when treatment begins.

A worked clinical vignette

A 4-year-old presents with two weeks of tiredness, pallor, easy bruising, and now fever with bone pain (he limps). Exam shows petechiae and mild lymphadenopathy. The blood count: hemoglobin 7 g/dL, platelets 25,000, white count 22,000 with many primitive cells reported. Reasoning: pancytopenia of the normal lines plus circulating blasts equals acute leukemia; age 2–5 and lymphadenopathy point strongly to ALL. The next steps are a bone marrow aspirate and flow cytometry to confirm lineage, and a lumbar puncture because ALL seeds the CNS. This child, treated on a modern protocol, has roughly a 90% chance of cure.

Diagnosis: From Film to Molecule

Diagnosis is a layered process, each layer answering a sharper question.

1. Full blood count and peripheral smear. The cheapest and fastest clue. Blasts on the film, cytopenias, and clues like Auer rods (needle-like inclusions, pathognomonic for AML) or smudge cells (fragile CLL lymphocytes) orient the diagnosis immediately.
2. Bone marrow aspirate and trephine biopsy. Acute leukemia is defined by 20% or more blasts in the marrow (WHO criterion). The biopsy also shows cellularity and fibrosis.
3. Flow cytometry (immunophenotyping). Cells are tagged with antibodies to surface markers (CD antigens) to prove lineage — myeloid (e.g. CD13, CD33, MPO), B-lymphoid (CD19, CD10), or T-lymphoid (CD3). This is how AML and ALL are definitively separated, which is essential because their treatments differ completely.
4. Cytogenetics and molecular studies. Karyotyping, FISH, and PCR/next-generation sequencing detect abnormalities like BCR-ABL1, the PML-RARA fusion of acute promyelocytic leukemia, FLT3 and NPM1 mutations in AML, and the deletions of CLL. These now drive both prognosis and drug choice, and are used to track measurable residual disease (MRD) during therapy.

Modern classification (WHO 2022 and ICC) has moved away from morphology alone toward genetic definition — many AML subtypes are now named by their driver mutation, because the mutation predicts behavior better than the way the cell looks.

Modern Therapy by Type

AML is treated with intensive induction chemotherapy (classically "7+3": cytarabine plus an anthracycline) aimed at clearing blasts to achieve remission, followed by consolidation and, in high-risk disease, allogeneic stem-cell transplant. Targeted agents now supplement this: FLT3 inhibitors (midostaurin), IDH inhibitors, and the BCL-2 inhibitor venetoclax with a hypomethylating agent for older or unfit patients. One subtype, acute promyelocytic leukemia (APL), is a special case — once the most rapidly fatal (from catastrophic bleeding/DIC), it is now often cured without conventional chemotherapy using all-trans retinoic acid (ATRA) plus arsenic trioxide, which force the malignant cells to mature. APL is a medical emergency: start ATRA on clinical suspicion, before genetic confirmation.

ALL treatment is a long, phased regimen — induction, consolidation, and prolonged maintenance over 2–3 years — with mandatory CNS-directed therapy (intrathecal chemotherapy) because the drugs otherwise cannot reach the "sanctuary site" of the brain. Relapsed or refractory B-ALL is now attacked with immunotherapy: blinatumomab (a bispecific antibody engaging T cells against CD19), inotuzumab, and CAR-T cells (the patient's own T cells re-engineered to target CD19).

CML is the triumph of targeted therapy. Because a single lesion (BCR-ABL1) drives the disease, tyrosine kinase inhibitors (TKIs) — imatinib and successors like dasatinib and nilotinib — control it with a daily oral pill. Response is monitored by quantitative PCR for BCR-ABL1 transcript levels; patients in deep, durable molecular response may even attempt treatment-free remission. Life expectancy now approaches normal.

CLL is often just watched when asymptomatic ("watch and wait"), because treating early does not help. When treatment is needed, targeted oral agents dominate: BTK inhibitors (ibrutinib, acalabrutinib) and the BCL-2 inhibitor venetoclax, frequently sparing patients traditional chemotherapy altogether.

Real-World Applications

• Recognizing the emergency: A febrile patient with a new pancytopenia and blasts on the film needs same-day hematology referral, not a "come back next week" — untreated acute leukemia kills quickly, and neutropenic sepsis is immediately life-threatening.
• Tumor lysis syndrome: When bulky leukemia is treated, dying cells dump potassium, phosphate, and uric acid, risking arrhythmia and renal failure. Prophylaxis with hydration and allopurinol or rasburicase is standard practice on every oncology ward.
• Monitoring by molecule: CML management is a real-world example of "treat to a number" — clinicians titrate and switch therapy based on PCR transcript milestones at 3, 6, and 12 months.
• Everyday primary care: A lymphocytosis discovered on a routine blood count in an older adult is frequently early CLL — usually reassuring, but it needs confirmation and follow-up rather than dismissal.

Common Mistakes

1. "A high white-cell count means the immune system is strong." Wrong — in leukemia the excess cells are dysfunctional blasts or clonal cells. Functional neutropenia leaves the patient immunocompromised despite the alarming number. The correction: judge immune status by functional neutrophils, not the total count.
2. "Acute means it just started; chronic means it's been there a long time." This confuses tempo with maturation. Acute versus chronic is defined biologically by the maturity of the malignant cells (blasts vs differentiated cells), not by how recently symptoms began. An "acute" leukemia is one made of immature blasts, full stop.
3. "All leukemias are treated with chemotherapy." Increasingly false. CML is managed with oral TKIs, APL often needs no conventional chemo (ATRA + arsenic), and CLL and relapsed ALL rely on targeted agents and immunotherapy. The correction: treatment is dictated by lineage and molecular genetics.
4. "Leukemia and lymphoma are the same thing." They overlap but differ in location: leukemias are primarily in the blood and marrow, lymphomas are solid masses in lymph nodes/tissues. The same lymphoid clone can present as either (e.g. lymphoblastic leukemia vs lymphoma).

Comparison and Connections

Feature	Acute leukemia	Chronic leukemia
Cells	Blasts (immature)	More mature cells
Onset	Days to weeks	Months to years
If untreated	Fatal in weeks–months	Survival often years
Marrow failure	Prominent early	Late
Typical discovery	Symptomatic (sick patient)	Often incidental

Leukemia sits alongside two neighbors students confuse. Lymphoma shares the lymphoid clone but presents as tissue masses. Myelodysplastic syndromes (MDS) are marrow-failure states that can transform into AML — think of MDS as "pre-leukemia" with under-20% blasts. Multiple myeloma is a related marrow malignancy but of plasma cells producing paraprotein. All are clonal disorders of hematopoiesis, differing in which cell transformed and where it accumulates.

Practice Questions

Recall

Q: Name the four major leukemia types by their two-axis classification. A: AML (acute myeloid), ALL (acute lymphoblastic), CML (chronic myeloid), CLL (chronic lymphocytic).

Understanding

Q: Why can a patient with a white-cell count of 90,000 still be at high risk of infection? A: Because the count is composed of dysfunctional leukemic blasts, not competent neutrophils. Effective immunity depends on functioning mature neutrophils, which are actually reduced (functional neutropenia). The high number is misleading.

Application

Q: A middle-aged adult has fatigue, splenomegaly, a white count of 150,000 with the full spectrum of maturing granulocytes, and a low blast count. What is the likely diagnosis, the defining genetic lesion, and the treatment class? A: Chronic myeloid leukemia. The defining lesion is the Philadelphia chromosome producing the BCR-ABL1 fusion gene. First-line treatment is a tyrosine kinase inhibitor (e.g. imatinib).

Analysis

Q: Explain why the Philadelphia chromosome discovery was scientifically pivotal beyond CML itself. A: It was the first recurrent chromosomal abnormality consistently linked to a specific human cancer, providing hard evidence that cancer can arise from a defined genetic event. Identifying the translocation (Rowley) and then the constitutively active BCR-ABL1 kinase established the mechanism, and imatinib proved that rationally targeting a cancer's specific molecular driver could work — launching the entire field of targeted therapy.

FAQ

Is leukemia inherited? Almost always no. It arises from acquired (somatic) mutations during a person's life. A few inherited syndromes (e.g. Down syndrome, Li-Fraumeni) raise risk, and rare familial predispositions exist, but the vast majority of cases are sporadic and not passed to children.

What causes it? Usually the cause is unknown. Established risk factors include ionizing radiation, certain chemicals (notably benzene), prior chemotherapy, some genetic conditions, and specific viruses (HTLV-1 for a rare T-cell leukemia). Most patients have no identifiable exposure.

Which leukemia is "best" to have? Prognosis varies enormously. Childhood ALL and CML now have excellent outcomes; CLL is often indolent and compatible with long life. AML in older adults remains the most challenging. But every case is individual, driven by genetics and fitness.

Is a bone marrow transplant always needed? No. Many patients — most CML and CLL, and childhood ALL — are treated without transplant. Allogeneic stem-cell transplant is reserved for high-risk or relapsed disease where the aim is to replace the marrow entirely and harness a graft-versus-leukemia effect.

How is leukemia different from anemia? Anemia is simply a low red-cell/hemoglobin level and has many benign causes. Leukemia is a cancer that can cause anemia (among other cytopenias) by crowding the marrow. Anemia is a finding; leukemia is a disease.

Can leukemia be cured? Yes for many patients. "Cure" is realistic in childhood ALL and APL, and CML is often controlled indefinitely as a chronic condition. Outcomes depend on type, genetics, age, and response to treatment.

Quick Revision

• Two axes: acute vs chronic (maturity of cells), myeloid vs lymphoid (lineage) → AML, ALL, CML, CLL.
• Acute = blasts, rapid, marrow failure triad: anemia, infection, bleeding. Diagnosis needs 20% or more marrow blasts.
• Auer rods → AML; smudge cells → CLL; lymphadenopathy + child → ALL.
• Diagnosis ladder: blood film → marrow → flow cytometry (lineage) → cytogenetics/molecular (prognosis + drug choice + MRD).
• Virchow named "leukemia" (white blood) in 1847.
• Philadelphia chromosome = t(9;22) → BCR-ABL1 kinase → CML → treated with TKIs (imatinib).
• APL: emergency, cured with ATRA + arsenic, not standard chemo. Start ATRA on suspicion.
• Watch for neutropenic sepsis, leukostasis, and tumor lysis syndrome.

Related Topics

Prerequisites

• Hematology overview
• Blood cell formation (hematopoiesis) — see Physiology

Related Topics

• Lymphomas (lymphoid malignancies presenting as tissue masses)
• Anemias and marrow failure syndromes
• Oncology for principles of cancer therapy

Next Topics

• Bone marrow transplantation
• Targeted therapy and immunotherapy in hematologic cancers
• Immunology for the basis of CAR-T and antibody therapies